Geftib Tablet contains Gefitinib 250 mg, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC). Gefitinib acts by blocking the intracellular phosphorylation of tyrosine kinase associated with the EGFR, thereby inhibiting tumor cell proliferation and inducing apoptosis in cancer cells expressing mutant EGFR. It is indicated for patients with locally advanced or metastatic NSCLC harboring specific EGFR mutations. The tablet is administered orally, with dosage and duration determined by the treating physician based on clinical response and tolerability. Common adverse effects include rash, diarrhea, nausea, and elevated liver enzymes, which should be monitored regularly. Patients should be advised to report any signs of interstitial lung disease, hepatotoxicity, or severe skin reactions promptly. Geftib Tablet should be used cautiously in patients with pre-existing liver impairment or pulmonary conditions. Drug interactions may occur with agents affecting cytochrome P450 enzymes, necessitating careful review of concomitant medications. Overall, Gefitinib provides a targeted therapeutic option in EGFR-mutated NSCLC, improving progression-free survival and quality of life when used as part of a comprehensive oncologic treatment plan.